SORAFENIB

SYNTHESIS http://newdrugapprovals.org/2014/06/26/bayer-healthcare-has-obtained-approval-from-the-japanese-ministry-of-health-labour-and-welfare-mhlw-for-its-nexavar-sorafenib-for-treatment-of-patients-with-unresectable-differentiated-thyroid-ca/

Bayer receives Canadian approval for Nexavar to treat differentiated thyroid cancer

Health Canada has approved Bayer’s Nexavar (sorafenib tablets) for treatment of patients with locally advanced or metastatic, progressive, differentiated (papillary/follicular/Hurthle cell) thyroid carcinoma, refractory to radioactive iodine. 53 more words